A new immunotherapy drug called VIR-5500 has produced what oncologists are calling 'remarkable' results in an early clinical trial for prostate cancer — a disease that has long stubbornly resisted immune-based treatments. Nearly half of the 58 patients in the trial saw their tumours shrink, with most experiencing only mild side effects.
The findings, presented in early 2026 by the UK's Institute of Cancer Research (ICR), represent a potential turning point for the most common cancer in men worldwide. Approximately 1.5 million men are diagnosed with prostate cancer every year globally.
**Why Prostate Cancer Resists Immunotherapy**
Immunotherapy has transformed outcomes for patients with many cancers. But prostate cancer has remained stubbornly 'immune-cold.' The tumour microenvironment suppresses immune activity, and few of the markers that conventional immunotherapy drugs target are present in prostate cancer cells. Despite decades of trying, no immunotherapy had truly cracked the disease — until now.
'Immunotherapy has transformed the outcomes for many people with cancer but for those with prostate cancer its benefits have often remained out of reach,' said Professor Kristian Helin, Chief Executive of the Institute of Cancer Research. 'It's encouraging to see this innovative approach showing promising effects in early clinical studies.'
**How VIR-5500 Works**
VIR-5500 is a T-cell engager — a type of drug that physically bridges immune T-cells to cancer cells, forcing a lethal encounter that the immune system would otherwise miss. The drug targets a protein called PRAME, which is expressed on many prostate cancer cells but largely absent from healthy tissue.
Crucially, VIR-5500 incorporates a dual-masking system that keeps it inactive until it reaches the tumour environment — reducing off-target toxicity, which is why most patients experienced only mild side effects.
**The Trial Results**
The Phase 1 trial enrolled 58 patients with advanced prostate cancer that had stopped responding to other treatments:
— Almost half of patients saw measurable tumour shrinkage — Most patients experienced only mild, manageable side effects — PSA levels dropped by 50% or more in 82% of patients at the highest doses — Several patients showed durable responses beyond the treatment period
'This is an exciting early signal,' said a researcher involved in the study. 'We're cautiously optimistic that this could open a new chapter in prostate cancer treatment.'
For the 375,000 men who die from prostate cancer globally each year, VIR-5500 represents something genuinely new: the first real sign that immunotherapy can work against a disease that has resisted it for decades. 💊
*Sources: Institute of Cancer Research (UK), Vir Biotechnology, Positive News, ASCO GU 2026*
